138 related articles for article (PubMed ID: 31450179)
1. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.
Couttenier A; Lacroix O; Silversmit G; Vaes E; De Schutter H; Robert A
Cancer Epidemiol; 2019 Oct; 62():101579. PubMed ID: 31450179
[TBL] [Abstract][Full Text] [Related]
2. Statin use is associated with improved survival in ovarian cancer: A retrospective population-based study.
Couttenier A; Lacroix O; Vaes E; Cardwell CR; De Schutter H; Robert A
PLoS One; 2017; 12(12):e0189233. PubMed ID: 29261726
[TBL] [Abstract][Full Text] [Related]
3. Use of ß-blockers and mortality following ovarian cancer diagnosis: a population-based cohort study.
Johannesdottir SA; Schmidt M; Phillips G; Glaser R; Yang EV; Blumenfeld M; Lemeshow S
BMC Cancer; 2013 Feb; 13():85. PubMed ID: 23433478
[TBL] [Abstract][Full Text] [Related]
4. Impact of metformin on gastric adenocarcinoma survival: A Belgian population based study.
Lacroix O; Couttenier A; Vaes E; Cardwell CR; De Schutter H; Robert A
Cancer Epidemiol; 2018 Apr; 53():149-155. PubMed ID: 29453032
[TBL] [Abstract][Full Text] [Related]
5. Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
Gonzalez R; Gockley AA; Melamed A; Sugrue R; Clark RM; Del Carmen MG; Growdon W; Berkowitz RS; Horowitz NS; Worley MJ
Gynecol Oncol; 2020 Jun; 157(3):700-705. PubMed ID: 32222327
[TBL] [Abstract][Full Text] [Related]
6. Impact of beta blockers on survival outcomes in ovarian cancer: a nationwide population-based cohort study.
Baek MH; Kim DY; Kim SO; Kim YJ; Park YH
J Gynecol Oncol; 2018 Nov; 29(6):e82. PubMed ID: 30207092
[TBL] [Abstract][Full Text] [Related]
7. Impact of beta blockers on epithelial ovarian cancer survival.
Diaz ES; Karlan BY; Li AJ
Gynecol Oncol; 2012 Nov; 127(2):375-8. PubMed ID: 22819786
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
Watkins JL; Thaker PH; Nick AM; Ramondetta LM; Kumar S; Urbauer DL; Matsuo K; Squires KC; Coleman RL; Lutgendorf SK; Ramirez PT; Sood AK
Cancer; 2015 Oct; 121(19):3444-51. PubMed ID: 26301456
[TBL] [Abstract][Full Text] [Related]
9. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.
Minlikeeva AN; Freudenheim JL; Cannioto RA; Szender JB; Eng KH; Modugno F; Ness RB; LaMonte MJ; Friel G; Segal BH; Odunsi K; Mayor P; Zsiros E; Schmalfeldt B; Klapdor R; Dӧrk T; Hillemanns P; Kelemen LE; Kӧbel M; Steed H; de Fazio A; ; Jordan SJ; Nagle CM; Risch HA; Rossing MA; Doherty JA; Goodman MT; Edwards R; Matsuo K; Mizuno M; Karlan BY; Kjær SK; Høgdall E; Jensen A; Schildkraut JM; Terry KL; Cramer DW; Bandera EV; Paddock LE; Kiemeney LA; Massuger LF; Kupryjanczyk J; Berchuck A; Chang-Claude J; Diergaarde B; Webb PM; Moysich KB;
Cancer Causes Control; 2017 May; 28(5):469-486. PubMed ID: 28293802
[TBL] [Abstract][Full Text] [Related]
10. Association between use of β-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease.
Grytli HH; Fagerland MW; Fosså SD; Taskén KA
Eur Urol; 2014 Mar; 65(3):635-41. PubMed ID: 23351721
[TBL] [Abstract][Full Text] [Related]
11. Beta-blocker use and survival after pancreatic cancer surgery: A nationwide population-based cohort study.
Kirkegård J; Cronin-Fenton D; Lund A; Mortensen FV
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5726. PubMed ID: 37946571
[TBL] [Abstract][Full Text] [Related]
12. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular medications and survival in people with ovarian cancer: A population-based cohort study from British Columbia, Canada.
Hanley GE; Kaur P; Berchuck A; Chase A; Grout B; Deurloo CM; Pike M; Richardson J; Terry KL; Webb PM; Pearce CL
Gynecol Oncol; 2021 Aug; 162(2):461-468. PubMed ID: 34090707
[TBL] [Abstract][Full Text] [Related]
14. Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.
Lacroix O; Couttenier A; Vaes E; Cardwell CR; De Schutter H; Robert A
Cancer Causes Control; 2019 Apr; 30(4):385-393. PubMed ID: 30820714
[TBL] [Abstract][Full Text] [Related]
15. β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Hicks BM; Murray LJ; Powe DG; Hughes CM; Cardwell CR
Ann Oncol; 2013 Dec; 24(12):3100-6. PubMed ID: 24050955
[TBL] [Abstract][Full Text] [Related]
16. The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma.
Al-Niaimi A; Dickson EL; Albertin C; Karnowski J; Niemi C; Spencer R; Shahzad MM; Uppal S; Saha S; Rice L; Nally AM
Gynecol Oncol; 2016 Dec; 143(3):521-525. PubMed ID: 27693123
[TBL] [Abstract][Full Text] [Related]
17. Effect of beta-blockers on cancer recurrence and survival: a meta-analysis of epidemiological and perioperative studies.
Yap A; Lopez-Olivo MA; Dubowitz J; Pratt G; Hiller J; Gottumukkala V; Sloan E; Riedel B; Schier R
Br J Anaesth; 2018 Jul; 121(1):45-57. PubMed ID: 29935594
[TBL] [Abstract][Full Text] [Related]
18. Pre- and post-diagnostic β-blocker use and lung cancer survival: A population-based cohort study.
Weberpals J; Jansen L; Haefeli WE; Hoffmeister M; Wolkewitz M; Herk-Sukel MPPV; Vissers PAJ; Brenner H
Sci Rep; 2017 Jun; 7(1):2911. PubMed ID: 28588274
[TBL] [Abstract][Full Text] [Related]
19. Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.
Cardwell CR; Pottegård A; Vaes E; Garmo H; Murray LJ; Brown C; Vissers PA; O'Rorke M; Visvanathan K; Cronin-Fenton D; De Schutter H; Lambe M; Powe DG; van Herk-Sukel MP; Gavin A; Friis S; Sharp L; Bennett K
Breast Cancer Res; 2016 Dec; 18(1):119. PubMed ID: 27906047
[TBL] [Abstract][Full Text] [Related]
20. Use of beta-blockers and risk of contralateral breast cancer.
Gottschau M; Bens A; Friis S; Cronin-Fenton D; Aalborg GL; Jensen MB; Ejlertsen B; Kroman N; Mellemkjaer L
Int J Cancer; 2022 May; 150(10):1619-1626. PubMed ID: 34985760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
